Euroapi

EAPI

Equity

ISIN FR0014008VX5 / Valor 118447738

Euronext - Euronext Paris (2025-11-21)

EUR 3.13+0.51%

Euroapi
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Euroapi stands as a prominent player in the pharmaceutical industry, specializing in the production and supply of Active Pharmaceutical Ingredients (APIs). With a portfolio boasting over 200 ingredients, the company caters to a diverse range of patient needs on a global scale, extending its reach to more than 80 countries. Euroapi's business model is centered on the innovation and sustainable development of API solutions, aiming to address the evolving demands of both customers and patients worldwide. This focus underscores the company's commitment to maintaining a pivotal role in the pharmaceutical supply chain, ensuring the availability of essential components for drug manufacturing across various therapeutic areas.

Summarized from source with an LLMView SourceSector: Finance

Net Sales and Revenue Performance

For Full-Year 2024, Euroapi’s net sales fell 10.0% to €911.9 million, driven by lower volumes for Sanofi and a temporary production suspension at Brindisi. The report highlights an 8.8% decline in API Solutions’ sales and challenges in CDMO revenues, despite some offsets from commercial momentum and new client additions.

Profitability and EBITDA Impact

The company posted a Core EBITDA of €50.4 million with a margin of 5.5%, down from 9.2% in 2023. This contraction resulted from unfavorable fixed cost impacts and exceptional costs related to the implementation of the FOCUS-27 plan, despite some positive contributions such as industrial performance and the impact of Buserelin’s stock clearance.

Cash Flow and Financing Improvements

Key progress was seen in cash flow management as Free Cash Flow before financing turned positive at €15.0 million, driven by tighter inventory management and improved cash collection. Additionally, Euroapi’s net cash position improved considerably to €25.2 million following a successful refinancing plan completed in Q3 2024.

Strategic Initiatives and Outlook

Euroapi is advancing its FOCUS-27 strategic plan towards sustainable and profitable growth, with encouraging progress in differentiated API sales and industrial rationalization. Looking ahead to 2025, the company anticipates a rebound in profitability through enhanced operational efficiencies while continuing efforts to protect cash flow and invest in future growth.

Summarized from source with an LLMView Source

Key figures

-8.43%1Y

-82.4%3Y

%5Y

Performance

55.9%1Y

80.7%3Y

76.2%5Y

Volatility